

WORLDWIDE HEALTHCARE TRUST PLC

Interim Management Statement – 3 months to 31 December 2010 (unaudited)

Worldwide Healthcare Trust PLC invests worldwide in pharmaceutical, biotechnology and related companies in the healthcare sector with the objective of achieving a high level of capital growth.

During the 3 month period ended 31 December 2010 the Company's undiluted net asset value per share total return was +2.3% and the share price total return was +1.7%, compared to a rise of 4.4% in the Company's benchmark, the MSCI World Health Care Index measured in sterling terms on a total return basis. The underperformance was due, in part, to mixed returns from some of the portfolio's large Biotechnology holdings, Japanese generic companies and also medical device stocks. During the three-month period a total of 358,607 shares were repurchased to be held in treasury at an average discount of 8.6%. Since the period end, to 9 February 2011, no further shares have been bought back by the Company. As at the date of this report there are 43,141,611 shares in issue.

In the period from 31 December 2010 to 9 February 2011, the Company's fully diluted net asset value per share total return was -1.6% and the share price total return was -1.0% compared to a fall of 0.8% in the Company's benchmark, all measured on a total return basis.

During the three month period and up to 9 February 2011, a total of 114,302 new shares were issued, raising £730,000 of additional funds for the Company, as a result of holders of subscription shares exercising their subscription rights. The next subscription date is 3 May 2011 and the subscription price is 638p per share. As at the date of this report there are 8,191,112 subscription shares in issue.

Trust Characteristics

	31 December 2010	30 September 2010
Number of holdings	59	57
Net assets (£m)	334.9	328.4
Yield	1.2%	1.2%
Gearing (AIC basis)	115	112
Share price (p)	702.00	690.00
NAV (p) -undiluted	777.67	756.86
NAV (p) diluted: sub shares	755.16	737.76
NAV (p) – fully diluted for sub shares and treasury shares	754.79	737.76*
(Discount)/premium (undiluted)	(9.7%)	(8.8%)
(Discount)/premium(diluted – sub shares)	(7.0%)	(6.5%)
(Discount)/premium (fully diluted)	(7.0%)	(6.5%)*
Subscription share price (p)	83.50	81.00

Source: *Frostrow Capital LLP*

*There were no shares held in treasury as at 30 September 2010.

10 Largest Investments

Name	% of portfolio at 31 December 2010	% of portfolio at 30 September 2010
Merck	6.0	5.9
Roche	6.0	5.4
Pfizer	5.4	6.9
Novartis	5.0	8.0
Johnson & Johnson	4.3	6.1
Genzyme	3.5	2.0
Bristol-Myers Squibb	3.5	4.4
Mitsubishi Tanabe	3.4	2.6
Amgen	2.5	2.4
GlaxoSmithKline	<u>2.2</u>	<u>2.2</u>
	41.8	45.9

Source: *Frostrow Capital LLP*

Sector Analysis

	% of portfolio at 31 December 2010	% of portfolio at 30 September 2010
Large capitalisation	65.7	63.9
Small capitalisation	34.3	<u>36.1</u>
Total	100.0	100.0

Source: Frostrow Capital LLP

Geographical Analysis

	% of portfolio at 31 December 2010	% of portfolio at 30 September 2010
North America	64.9	64.1
Europe	21.1	24.3
Far East	13.2	11.6
Israel	0.8	=
Total	100.0	100.0

Source: Frostrow Capital LLP

Total Return Performance to 31 December 2010

	3 Months	1 Year	3 Years	5 Years
Share price	+1.7%	+15.5%	+45.8%	+29.1%
NAV Fully diluted	+2.3%	+17.7%	+47.0%	+40.8%
Benchmark*	+4.4%	+8.8%	+35.4%	+34.5%

Source: NAV (total return; fully diluted) and Share Price (total return) Morningstar. Benchmark – Thomson Reuters

* Benchmark – Blended Datastream World Pharmaceutical and Biotechnology Index/MSCI World Health Care Index, both measured in sterling terms on a total return basis. With effect from 1 October 2010, the performance of the Company is measured against the MSCI World Health Care Index measured on a total return basis in sterling terms. Prior to this date, performance was measured against the Datastream World Pharmaceutical and Biotechnology Index on a total return basis in sterling terms.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide information to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules.

This Interim Management Statement is available on the Company's website www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available, together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares – 0338530

Subscription Shares – B3VMCB0

ISIN –

Shares – GB0003385308

Subscription Shares – GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

16 February 2011